The authors focused on the equivalence criteria by which the potential manufacturers of generic versions of LMWHs are required to adhere to guidelines for demonstration of clinical and biologic equivalence of generic products. They also commented on the non-requirement for clinical trials of generic products because the regulatory agency stipulates that a generic drug produced by exactly the same patent/manufacturing conditions is expected to behave similarly to the branded drug. While this may be true for synthetic drugs such as warfarin and clopidogrel, this issue requires additional review and discussion in the case of complex mucopolysaccharidederived agents such as the LMWHs. In the authors' view, the development of generic versions of LMWHs is inevitable. This statement is valid because, at the submission of this commentary, two companies have already filed an Abbreviated New Drug Application (ANDA) for generic versions of enoxaparin. Several other companies are in the process of filing for approval from the regulatory agencies to allow marketing of generic versions of LMWHs.
On June 26, the FDA accepted the application The history of LMWH development reveals current practice of the approval process. It is interesting that both the FDA and several European agencies have allowed manufacturers of branded LMWHs to substitute considerably changed products for the original product, merely controlling the molecular weight or a specified biologic activity.
The first LMWH, Nadroparin' (Fraxiparin; Sanofi-Synthelabo) was originally produced by ethanolic precipitation of porcine heparin followed by chromatographic separation. Due to limited yield, it was not possible to manufacture this drug in large enough amounts to meet the market demand. The manufacturer then produced a nitrous acid depolymerized product, which exhibited a molecular weight profile and anti-Xa to anti-Ila ratio similar to that of the ethanolic-derived product (1, 2) . The European regulatory agency approved the equivalence of the natural and depolymerized versions of this drug without requiring any chemical data. Eventually the company replaced the original fraxiparin with the chemically depolymerized version.
The currently marketed version of Tinzaparin® (Logiparin; Leo/Pharmion) is a product with considerably higher molecular weight than the originally introduced product (6400 vs. 4300 D). The manufacturer refined the initial process by eliminating the ultra-low-molecular-weight fractions from this drug (<1500 D). Thus, the resulting mean molecular weight was higher. The biologic activity in terms of anti-Xa activity, however, was not modified. Despite this major change, the regulatory agencies accepted the modification of the final processing and required only phase I bioequivalence data in terms of anti-Xa and anti-Ila to approve the modified product (3) .
These examples attest to the flexibility of the regulatory bodies to accept products with similar but not exactly the same molecular and biologic characteristics and call them the same. It would thus appear that if a generic manufacturer uses a process patent, it is relatively assured that the resulting product would be approved by the FDA.
Because of the complex nature of LMWHs, one should question the adequacy of the current requirements for acceptance of these drugs, be it an original or a generic, by the regulatory agencies. To demonstrate the similarities and differences among various LMWH products, several systematic approaches have been developed (4-6). We recommend, that in the case of generic LMWHs, the regulatory bodies have to reconsider their criteria for accepting a generic equivalent. The following lists some of the basic requirements for characterizing a LMWH, which should be used in determining approval of a product as a true generic:
1. Physiochemical equivalence 2. Biologic equivalence 3. Pharmacologic and toxicologic equivalence 4 . Dosage equivalence in animal models for specific indications Besides the physicochemical and biologic equivalence, a generic equivalent of a branded drug should also exhibit pharmacologic and toxicologic equivalence at the dosage stipulated in phase I or equivalent clinical trials. All studies should be carried out over a dosage range where the branded drug will be used.
Various regulatory agencies such as the FDA, EMEA, and WHO consider each of the LMWHs to be a distinct drug. However, these agencies only consider molecular weight profile and anti-Xa/anti-IIa potency, which may not be adequate for the demonstration of generic product equivalence to the branded product. The branded LMWHs are only partially characterized if these limited specifications are used. A generic version of a brand named LMWH must be manufactured by exactly the same process as the original drug, but must, in addition, exhibit physical, chemical, biologic, and clinical equivalence.
It is well known that each of the branded LMWHs exhibits product-specific pharmcodynamic and pharmacokinetic differences. Data such as the molecular weight distribution of the components, structural characteristics, interactions with endogenous proteins, biologic actions such as the anti-Xa and anti-IIa, and other specific actions should also be identical. Physiochemical methods such as nuclear magnetic resonance, as well as oligosaccharide profiling including the structural distribution of various components and heparinase digestion signature profile can be used to prove the identity of a generic drug.
Current regulatory requirements do not consider all of these specifications, making it very likely that a generic product would not behave in a similar fashion as the original drug if the required characterization is not undertaken. Generic versions of each branded product can be manufactured with methods described in each of the individual patents of the branded products. However, certain specific differences may still exist that can only be demonstrated in biologic assays and dosage optimization studies in clinical trials.
Initially wide lot-to-lot variations were observed between batches of the same branded product. It is expected that the generic equivalent agents may also exhibit similar variations. The impact of these batch variations on each product should be documented on the clinical outcome. Some regulatory stipulations on the batch-tobatch variations should also be addressed.
The recent citizen's petition submitted to the FDA by Aventis stipulates the following points as related to enoxaparin: 1. The product is unique. The product is not fully characterized. Not until full characterization has been completed, can a generic product be authorized. 2. Clinical trials are needed to prove the clinical equivalence of the generic product.
The first argument of the citizen's petition also holds true for unfractionated heparin. Heparin is obtained from various natural sources, different salts are prepared, and impurities are known to exist within the products. Heparin has never been fully characterized in terms of its molecular and biologic actions. With use of new techniques, we are still learning about this drug. Heparin was initially used as a antithrombotic agent in 1930s. Due to the physiochemical heterogeneity of this complex drug, a standard was established in 1942 (7) . The standardization practices at regulatory levels used the concept "like versus like" to standardize this drug.
Similarly, LMWH standards for the molecular profile and potency in terms of anti-Xa potency have been used to standardize various LMWH preparations (8, 9) . These standards are only useful in the molecular weight profile and anti-Xa/anti-Ila potency evaluation. These described standardization and cross-referencing methods in various publications and European Pharmacopoeia represents conventional methods that have been used for the characterization of unfractionated heparin and LMWHs may not be adequate for the specific characterization of generic versions of LMWHs. To demonstrate the equivalence of the generic products to the branded products, additional analytical and pharmacologic data may be needed. Several reports on the differences in the pharmacokinetic and pharmacodynamic profile of various LMWHs have clearly shown a discordance between the anti-Xa activity and the overall biologic actions of these agents (10) . Thus, the standardization of the biologic actions of LMWHs is of limited value in terms of establishing equivalence for not only different branded LMWHs but for the characterization of the generic LMWHs. A integrated profile may be more relevant for this process.
The citizens petition submitted on behalf of Aventis to the commissioner of FDA requesting the agency to withhold approval of ANDA for a generic version of enoxaparin until the arbitrary conditions stated in this petition are satisfied may not be consistent with the accepted scientific and regulatory guidelines set forth by the agency and manufacturers of drugs. Enoxaparin represents a depolymerized heparin, which has been characterized by physical, chemical, and biologic terms. As a matter of fact, the characteristics of the final product are publicly described by both the company and scientific community using the originally published procedure and the information in the patent. Therefore enoxaparin equivalent products with chemical and pharmacologic equivalence can be produced. The chemical process of depolymerization using benzyla-tion of porcine mucosal heparin followed by alkaline hydrolysis resulting in the formation of oligosaccharide chains in fact contains a 1,6-anhydro ring structure at the reducing ends and this chemical moiety can be easily adjusted between 15% and 25% of total poly/oligosaccharide components. This therefore may not be a unique feature of the branded product.
On the other hand, it is conceivable that each of the branded LMWHs may have some unique microchemical or physical feature that may not be reproducible by merely using the process described in the patent. Additional guidelines requiring specific structural information will be needed to reinforce the requirements for molecular and structural characterizations. However, because some of these attributes may not have been described in the original patent, addition of such previously unreported characteristics may be contested by the manufacturer of the generic version. In our opinion, although not reported in the patent, these characteristics had always existed but were not revealed by virtue of the technology and knowledge that did not exist at the time of the patent filing. Once known, these characteristics need to be accepted as defining the original product. Manufacturers may therefore provide additional information on the product characterization as it becomes available. However, a generic product should only be approved if it complies with existing specifications for a given product.
Regarding the second argument of the citizen's petition of Aventis, in reference to the requirement for clinical equivalence trials, the authors currently point to the Drug Price Competition and Patent Term Restoration Act (www.fda.gov). This act waived the requirement for the duplicate safety and efficacy testing in humans for testing generic equivalent products to the branded drug. The generic drug review process is clearly outline by the FDA in which bioequivalency is a mandatory requirement. Because of the multiple biologic actions of LMWHs, specific guidelines may be needed to demonstrate bioequivalency. Furthermore, because of their use in critical clinical settings such as acute coronary syndrome and pulmonary embolism, specific guidelines should be developed to obtain data on clinical equivalence for generic LMWHs. The FDA has only granted product and indication specific approval for these drugs. Thus, a generic version of a branded LMWH can only be considered for the approved indications for the branded product.
At this time, there are no specific guidelines for the assessment of generic equivalent LMWHs. The existing guidelines from the Office of Generic Drugs may not be adequate for generic LMWHs. Because LMWHs represent a hybrid drug product between biologic and chemical entities, there is a need for developing specific guidelines for the acceptance of individual generic versions of branded LMWHs.
The regulatory bodies eventually may allow the generic versions of LMWHs and apply the same or expanded guidelines as for other biologicals. This may result in generic products that will meet these specifications, but in fact they may not be the same, and may therefore behave differently in clinical settings. It is important, therefore, to have additional requirements to provide supplementary chemical and biological data to support the filing of a generic version of a branded drug. Clinical trials may or may not be required for specific products for approved indications depending upon the filing process to evaluate data for the FDA review.
The generic pharmaceutical industry has played a key role in providing less expensive equivalents of original branded drugs that would not have been otherwise accessible to a large group of patients. Thus, the generic drugs have a major public health importance. Recognizing this, President Bush has already announced the expansion of the Office of Generic Drugs (11) . Thus, at a Federal level, there is endorsement of the development of generic drugs and to have them accessible to all patients.
In the case of generic versions of the LMWHs, it is clear that the manufacturers of the generic versions may not have adequate expertise to compare these different LMWHs in refined methods to assure clinical, biologic, and pharmacologic equivalence. Such studies should be carried out by independent research groups following establishment of specific guidelines.
We agree with the authors that the coming of generic drugs is inevitable; however, it is important that the generic products should be manufactured in strict compliance with the manufacturing specification of the branded product. Furthermore, regulatory agencies should require additional data on the chemical, biologic, pharmacologic/toxicologic, and dose-response relationship in specific settings.
The authors have provided a synopsis of some of the preliminary data on the comparison of a branded product with its available generic versions. While these data are limited, they do correctly point to the fact that pre-clinical studies to compare the equivalence of branded and generic agents will be of crucial importance for the possible acceptance of the generic LMWHs. Such guidelines should be developed by expert panels by a peer review process and endorsed by professional and regulatory organizations.
